New Biomarkers in Cancers

Message from the Guest Editor

Dear Colleagues,

In recent years, several new therapies have been approved for different cancer entities. Due to these new therapeutic options, physicians are confronted with new challenges, such as monitoring progression and stratifying patients for appropriate treatments.

Novel analytical techniques using body fluids such as blood and tumor tissue have identified numerous possible biomarkers.

In this Special Issue, we will publish reviews and original research that provide new insights into the role of predictive and prognostic tumor biomarkers. Novel insights into tumor biomarkers are particularly welcome.

Prof. Dr. Jochen Sven Utikal
Guest Editor
**Editor-in-Chief**

Prof. Dr. Samuel C. Mok  
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

**Message from the Editor-in-Chief**

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

**Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.  

**High visibility:** indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews, Scopus and other databases. Citations available in PubMed, full-text archived in PubMed Central.  

**Rapid publication:** manuscripts are peer-reviewed and a first decision provided to authors approximately 16.9 days after submission; acceptance to publication is undertaken in 4.2 days (median values for papers published in this journal in the second half of 2018).

**Contact Us**

*Cancers*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
Fax: +41 61 302 89 18  
www.mdpi.com  
mdpi.com/journal/cancers  
cancers@mdpi.com  
@Cancers_MDPI